Eagle Bay Advisors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Eagle Bay Advisors’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-210	Closed	-$2.11K	–	1007
2023 Q4	$2.11K	Hold	210	–	–	﹤0.01%	737
2023 Q3	$605	Hold	210	–	–	﹤0.01%	815
2023 Q2	$800	Hold	210	–	–	﹤0.01%	808
2023 Q1	$391	Hold	210	–	–	﹤0.01%	881
2022 Q4	$483	Hold	210	–	–	﹤0.01%	886
2022 Q3	$1K	Hold	210	–	–	﹤0.01%	894
2022 Q2	$1.16K	Buy	+210	New	+$653	﹤0.01%	896
2022 Q1	–	Sell	-160	Closed	-$1K	–	1029
2021 Q4	$1K	Hold	160	–	–	﹤0.01%	1082
2021 Q3	$2K	Hold	160	–	–	﹤0.01%	1012
2021 Q2	$3K	Buy	+160	New	+$2.14K	﹤0.01%	809

Eagle Bay Advisors's GRCL Position: Q1 2024 in Review

Eagle Bay Advisors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 210 shares — an estimated $2.11K sold.

Eagle Bay Advisors first reported a position in GRCL in Q2 2021 and held it in 10 quarters. The position peaked at $3K in Q2 2021. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Eagle Bay Advisors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Eagle Bay Advisors sold 210 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $2.11K.
Eagle Bay Advisors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2021 and held it in 10 quarters.
Eagle Bay Advisors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $3K in Q2 2021.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Eagle Bay Advisors's 13F filing for Q1 2024, filed 8 May 2024.